DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE: BAX), a global leader in renal care, and Satellite Healthcare, a leading, national not-for-profit and the sixth largest provider of patient-centered dialysis and kidney disease services in the U.S.,1 today announced an agreement to provide patients with the latest advancements in peritoneal dialysis, hemodialysis and continuous renal replacement therapy.
Under the four-year agreement, Satellite Healthcare plans to offer AMIA Automated Peritoneal Dialysis (APD) system with SHARESOURCE to peritoneal dialysis (PD) patients, and integrate REVACLEAR into its high-flux hemodialysis therapy offering at its 80 Satellite Dialysis and Satellite WellBound home dialysis centers that serve more than 7,000 patients nationwide. Details of the agreement were not disclosed.
''Baxter and Satellite Healthcare share a common goal to provide patients with a better dialysis experience,'' said Giuseppe Accogli, corporate vice president and president, Baxter Renal. ''We are pleased to continue our relationship with an organization that is clearly leading the way and revolutionizing how kidney disease patients are cared for in the U.S.''
Satellite Healthcare launched Re-Imagine Home, a long-term initiative to change the landscape of home dialysis with the design of an industry-leading home dialysis model. The aspirational goal through Re-Imagine Home is to double Satellite Healthcare’s home dialysis usage from 20% to 40% of its patient population and increase awareness of home dialysis.
''Our mission is to make life better for our kidney disease patients by offering a personalized care experience that is unlike any other,'' said Satellite Healthcare CEO Rick Barnett. ''AMIA, Baxter’s new technology, is a foundational tool for Satellite Healthcare in reaching our Re-Imagine Home goal to make home dialysis an accessible and effective modality option for more dialysis patients.''
AMIA APD System with SHARESOURCE
Baxter’s AMIA APD system with SHARESOURCE, which was launched in late 2015, was designed to help more patients manage therapy at home. The system’s patient-centric features include voice guidance, a touchscreen control panel and SHARESOURCE, Baxter’s cloud-based telemedicine platform.
Clinicians can use SHARESOURCE to securely and remotely manage their home dialysis patients. SHARESOURCE provides clinicians with on-demand access to dialysis-related treatment data, which automatically collects after each PD session, and the ability to remotely adjust device programs.
REVACLEAR High-Flux Dialyzer
Dialyzers serve an important function during hemodialysis, as they act as a filter to remove toxins from the blood. REVACLEAR, a high-flux dialyzer, contains a three-layer polyarylethersulfone membrane, which has been designed to provide selective permeability and minimal resistance to diffusion.2 REVACLEAR dialyzers are indicated for treatment of chronic and acute renal failure by hemodialysis.
About Satellite Healthcare
Satellite Healthcare has been among the nation's leading not-for-profit providers of kidney dialysis and related services since 1974. Through its affiliated services, Satellite WellBound, Satellite Dialysis, and Satellite Research, Satellite Healthcare provides unparalleled early patient wellness education, personalized clinical services, and a complete range of dialysis therapy choices. In addition, Satellite Healthcare has a well-recognized, enduring commitment to philanthropy and community service, from funding millions of dollars in research grants to sponsoring kidney programs nationwide. Satellite is committed to advancing the standard of chronic kidney disease care so patients can enjoy a better life.
Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
This release includes forward-looking statements concerning Baxter's REVACLEAR dialyzer and related performance data, including anticipated benefits associated with its use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: product quality, manufacturing or supply issues; patient safety issues; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; the impact of competitive products, pricing and disruptive technologies; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements
1 Nephrology News & Issues 2016 10 Largest Dialysis Providers Report, Figure 1. http://www.nephrologynews.com/largest-dialysis-providers-2016-poised-change/. Accessed 8/18/16.
2 Ronco C, et al. Nephrol Dial Transplant 2003; 18 (Suppl 7):vii10–vii20; Ward RA & Ouseph R. Abstract presented at the 40th ASN congress. San Francisco (USA). 2007. [abstract SA-PO510]; Bhimani JP, et al. Nephrol Dial Transplant 2010; 25:3990–3995; Data on file. May 2013. Nilsson LG, Beck W and Bosch J. REVACLEAR White Paper. (USMP/MG3/140052).